Apollon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Apollon Wealth Management's VRTX Position: Q1 2026 in Review
Apollon Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 32% in Q1 2026, buying an estimated $4.38M and bringing the position to 38,595 shares worth $17.2M. The position accounts for 0.28% of the portfolio, ranked #79.
Apollon Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 19 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Apollon Wealth Management held 38,595 shares of Vertex Pharmaceuticals worth $17.2M as of Q1 2026.
- Apollon Wealth Management bought 9,400 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.38M.
- Vertex Pharmaceuticals made up 0.28% of Apollon Wealth Management's portfolio in Q1 2026, its #79 holding.
- Apollon Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.